Differences

This shows you the differences between two versions of the page.

--- stephanie_carlin [2022/05/01 20:43]
liam [University of Toronto]
+++ stephanie_carlin [2022/05/01 20:55] (current)
liam [Funding]
@@ Line 12: / Line 12: @@
 Carlin recently finished an advanced practice pharmacy residency in [[thrombosis]] at [[Sunnybrook Health Sciences Centre]] through the [[University of Toronto]].((Carlin, S., Geerts, W., & Khosravani, H. (2021). //The clot thickens—enhanced integration of stroke and thrombosis training.// Journal of Thrombosis and Thrombolysis, 53(1), 17–19. https://doi.org/10.1007/s11239-021-02502-7))
 ===== Career and Affiliations =====
 ==== Hamilton Health Sciences ====
-Carlin is a critical care pharmacist at [[Hamilton Health Sciences]].((//Stephanie Carlin · Pharmacist · Hamilton Health Sciences.// OpenGovCA. Retrieved May 1, 2022, from https://web.archive.org/web/20220501183726/https://opengovca.com/ontario-employee/stephanie-carlin))
+Carlin was a critical care pharmacist, and now a thrombosis pharmacist, at [[Hamilton Health Sciences]].((//Stephanie Carlin · Pharmacist · Hamilton Health Sciences.// OpenGovCA. Retrieved May 1, 2022, from https://web.archive.org/web/20220501183726/https://opengovca.com/ontario-employee/stephanie-carlin))
 ==== Ontario COVID-19 Science Advisory Table ====
 Carlin is a member of the Drugs & Biologics Clinical Practice Guidelines Working Group of the [[Ontario COVID-19 Science Advisory Table]].((//About Us.// Ontario COVID-19 Science Advisory Table. Retrieved April 28, 2022, from https://covid19-sciencetable.ca/about/))
+===== Research =====
+Her research interests include optimization of antithrombotic use in clinical practice.
+==== Funding ====
+Carlin received funding from [[pharmaceutical_companies:Sanofi]] for her advanced
+practice thrombosis residency program.((Carlin, S. (2021, February 10). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://web.archive.org/web/20220501184628/https://covid19-sciencetable.ca/wp-content/uploads/2021/02/Declaration-of-Interest_Drugs-and-Biologics-Clinical-Practice-Guidelines-Working-Group_Stephanie-Carlin-1.pdf))
+She also received joint payment from [[pharmaceutical_companies:Bristol-Myers Squibb]] and [[pharmaceutical_companies:Pfizer]] for an "educational presentation to health professionals on atrial fibrillation.((Carlin, S., & Eikelboom, J. (2022). //Advances in anticoagulation: patients with bioprosthetic heart valves.// Cardiovascular Research, 118(3), e26–e28. https://doi.org/10.1093/cvr/cvab360))